Literature DB >> 19395632

Ocular telemedicine between Nepal and the USA: prevalence of vitreoretinal disease in rural Nepal.

J N Ulrich1, G Poudyal, S J Marks, T R Vrabec, B Marks, A B S Thapa, M K Shresta, S Ruit, J L Federman.   

Abstract

This study is aimed at reporting experiences with telemedicine between Nepal and the USA and at reporting the prevalence of age-related macular degeneration (AMD) and diabetic retinopathy (DR) in rural Nepal. AMD and DR are becoming more significant factors for non-reversible vision loss in rural Nepal due to increasing life expectancy and urbanisation. The prevalence of DM is low compared with the developed world, but the percentage of diabetics with DR is high, presumably due to limited access to healthcare. The higher prevalence of DM in Hetauda is explained as being due to a more urban lifestyle, dietary habits (more deep-fried food) and more advanced age.

Entities:  

Mesh:

Year:  2009        PMID: 19395632     DOI: 10.1136/bjo.2008.151357

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  4 in total

1.  Telerehabilitation for people with low vision.

Authors:  Ava K Bittner; Patrick D Yoshinaga; Stephanie L Wykstra; Tianjing Li
Journal:  Cochrane Database Syst Rev       Date:  2020-02-27

Review 2.  Telerehabilitation for people with low vision.

Authors:  Ava K Bittner; Stephanie L Wykstra; Patrick D Yoshinaga; Tianjing Li
Journal:  Cochrane Database Syst Rev       Date:  2015-08-31

3.  Implementation and first-year screening results of an ocular telehealth system for diabetic retinopathy in China.

Authors:  Jinjuan Peng; Haidong Zou; Weiwei Wang; Jiong Fu; Bingjie Shen; Xuelin Bai; Xun Xu; Xi Zhang
Journal:  BMC Health Serv Res       Date:  2011-10-04       Impact factor: 2.655

Review 4.  Telemedicine for the Diagnosis and Management of Age-Related Macular Degeneration: A Review.

Authors:  Grayson W Armstrong; John B Miller
Journal:  J Clin Med       Date:  2022-02-05       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.